MD Anderson Cancer Center said on Tuesday that oncologists will be able to access a database to help them identify approved treatments and available clinical trials based on the genetic alterations detected in their patients' cancers.
MD Anderson developed the Precision Oncology Decision Support System via Philips' oncology informatics solution. Given the rapid pace of genomic advancements and the increasing availability of new precision oncology options, MD Anderson decided to run PODS on Philips' informatics solution and offer clinicians a streamlined view of the therapeutic and study options in the context of patients' genomic profile.
"Today, pathologists and oncologists are faced with the challenges of keeping abreast of the increasing number of therapy options and the rapid advances in genomic testing, the molecular findings of which require increasingly specialized expertise to interpret," MD Anderson and Philips said in a joint statement. "The growing amount of evidence for newly approved targeted and immune-oncology therapies necessitates solutions to simplify the complexity. Philips and MD Anderson aim to help pathologists and oncologists serve their patients and provide them with therapeutic options and relevant clinical trials based on tumor markers."
This story first appeared in our sister publication, Genomeweb.